Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
IPO Year: 2014
Exchange: NASDAQ
Website: secondsight.com
| Date | Price Target | Rating | Analyst |
|---|
Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ:VANI) (the "Company" or "Vivani") announced that trading of the Company's common stock on The Nasdaq Capital Market under the symbol "VANI" will commence today. Vivani is the combination of Nano Precision Medical, Inc. ("NPM") and Second Sight Medical Products, Inc. Closing of the merger was completed and announced yesterday, August 30, 2022. Vivani leverages proprietary technologies to develop and commercialize drug and device implants that treat patients with chronic diseases with high unmet medical need. Vivani has approximately $55 million in cash to advance the development of its portfolio, which includes lead asset N
Vivani will be traded under the new ticker (NASDAQ:VANI) Second Sight Medical Products, Inc.(NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, Inc. ("NPM"). NPM is a biopharmaceutical business which develops miniaturized, subdermal drug implants utilizing its proprietary NanoPortal™ technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. In connection with the merger, Second Sight changed its name to Vivani Medical, Inc
Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat
Grant proceeds support an ongoing early feasibility study of Orion Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health ("NIH") of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the "Orion Trial"), grant 5UH3NS103442. The NIH released $1.1 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to co
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. ("NPM"), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States. As previously announced, Second Sight and NPM have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and owned by Second
Nano Precision Medical's lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight shareholders will own ~23% of the combined company. Second Sight shareholders join NPM shareholders, including AstraZeneca which has been a strategic investor since 2016 Second Sight currently has over $69M to enable the advancement of NPM-119 through clinical proof of concept into a pivotal clinical trial and continued exploration of the visual prosthesis business opportunity Investor Conference Call Scheduled for Tuesday, February 8, 2022,
Grant proceeds support a patient preference information study of Orion subjects Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses. The study will help the Company better understand acceptable risks, necessary benefits, and appropriate risk/benefit balance for visual cortical pr
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or the "Company"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underwriter's option to purchase additional shares. The gross proceeds from the offering, including the exercise of the over-allotment option, were $57,500,000, before deducting underwriting discounts, commissions and other offering expe
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or the "Company"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock a
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or the "Company") a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offerin
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)
SC 13D - Vivani Medical, Inc. (0001266806) (Subject)
SC 13D/A - SECOND SIGHT MEDICAL PRODUCTS INC (0001266806) (Subject)
SC 13G/A - SECOND SIGHT MEDICAL PRODUCTS INC (0001266806) (Subject)
SC 13G - SECOND SIGHT MEDICAL PRODUCTS INC (0001266806) (Subject)
SC 13G/A - SECOND SIGHT MEDICAL PRODUCTS INC (0001266806) (Subject)
Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat
Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held May 28, 2021. Second Sight held its annual meeting online due to the COVID-19 pandemic. 60.98% of shareholders were present online or by proxy. Shareholders voted on four proposals: (1) electing six (6) members of the Board of Directors, to serve until the next annual meeting of shareholders in 2022 and until their successors are duly elected and qualified, (2) ratifying the appointment of Gumbiner Savett Inc. as our
Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market Aims to create a global leader with potential to treat nearly all forms of blindnessCombined company to trade on Nasdaq and benefit from business and development synergies in the U.S. and EuropeTransaction provides broader access to financing sources to enable the combined company to accelerate the development and commercialization of its productsPixium Vision to remain listed on Euronext Growth and to be the largest shareholder of the new combined company listed on NasdaqTransaction expected to close in late Q1 or the beginning of Q2 2021Conference Call s
8-K - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
10-Q - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
25 - Vivani Medical, Inc. (0001266806) (Filer)
S-8 - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Nano Precision Medical's lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight shareholders will own ~23% of the combined company. Second Sight shareholders join NPM shareholders, including AstraZeneca which has been a strategic investor since 2016 Second Sight currently has over $69M to enable the advancement of NPM-119 through clinical proof of concept into a pivotal clinical trial and continued exploration of the visual prosthesis business opportunity Investor Conference Call Scheduled for Tuesday, February 8, 2022,
Gainers GigaCloud Technology Inc (NASDAQ:GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) shares gained 80.2% to close at $0.91 after the company announced a marketing authorization application for pegzilarginase for the treatment of Arginase 1 deficiency has been submitted to and successfully validated by the European Medicines Agency. Social Capital Suvretta Holdings Corp. I (NASDAQ:DNAA) jumped 48.3% to settle at $14.07 following the completion of the SPAC merger with Akili. Axsome Therapeutics, Inc. (NASDAQ:AXSM) rose 40.4% to close at $59.55 after the company announce
Gainers GigaCloud Technology Inc (NASDAQ:GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. Volcon, Inc. (NASDAQ:VLCN) gained 51% to $2.7899 after the company announced it has received over $100 million of pre-production orders for the Stag Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) shares jumped 41.2% to $0.7131 after the company announced a marketing authorization application for pegzilarginase for the treatment of Arginase 1 deficiency has been submitted to and successfully validated by the European Medicines Agency. Axsome Therapeutics, Inc. (NASDAQ:AXSM) gained 41% to $59.84 after the company announced the U.S. FDA has approved Au
Gainers Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday. Eargo, Inc. (NASDAQ:EAR) shares rose 148% to $1.74 in pre-market trading. The company is scheduled to report Q2 earnings on Monday, August 8. Applied DNA Sciences, Inc. (NASDAQ:APDN) shares rose 63% to $4.57 in pre-market trading after jumping 297% on Tuesday. Applied DNA Sciences initiated analytical validation of a company-developed, PCR-based monkeypox virus test specific to the genetic signature of the monkeypox virus. Tuniu Corporation (NASDAQ:TOUR) shares rose 61% to $1.30 in pre-market trading after dropping over 9% on Tuesday. Chembio Diagnos
Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission.
https://twitter.com/PatentGrants/status/1549049927614902273
Gainers Qudian Inc. (NYSE:QD) rose 61.3% to $1.92 in pre-market trading after the company issued an update on its QD Food ready-to-cook meal business. AMTD Digital Inc. (NYSE:HKD) rose 40% to $22.70 in pre-market trading after gaining 108% on Friday. The company priced its IPO at $7 per share. ITHAX Acquisition Corp. (NASDAQ:ITHX) rose 31.4% to $18.39 in pre-market trading after jumping over 40% on Friday. ITHAX Acquisition’s shareholders approved business combination with Mondee. Intelligent Living Application Group Inc. (NASDAQ:ILAG) rose 25.8% to $2.83 in pre-market trading after declining 11% on Friday. The company reported closing of $20.24 million initial public offering. Ver
Second Sight Medical Products, Inc. (NASDAQ:EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (“NIH”) of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the “Orion Trial”), grant 5UH3NS103442. The NIH released $1.1 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial. The funding supports continuation of this impo
The Federal Open Market Committee opted to raise fed funds rates by 0.75% on Wednesday to a new target range of between 1.5% and 1.75%. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3 HCW Biologics The Trade: HCW Biologics Inc. (NASDAQ:HCWB) Chief Financial Officer Rebecca Byam acquired a total
US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3 Second Sight Medical Products The Trade: Second Sight Medical Products, Inc. (NASDAQ:EYES) Director Gregg Williams acquired a total of 312,493 shares at an average price of $2.30. To acqui